<DOC>
	<DOCNO>NCT01596868</DOCNO>
	<brief_summary>The present study randomize , control , phase II study locally advance nasopharyngeal carcinoma ( NPC ) Northwest China treat Gemcitabine plus cisplatin regimen ( GP ) Docetaxel plus cisplatin regimen ( TP ) induction chemotherapy follow concurrent chemoradiotherapy . The population consist stage III-IVb nasopharyngeal carcinoma ( NPC ) . The effectiveness , side effect quality life evaluate accord Standard WHO response criterion , NCI-CTC AE V3.0 EORTC QLQ-C30 H &amp; N35 questionnaire .</brief_summary>
	<brief_title>GP VS TP Treatment Advanced Nasopharyngeal Carcinoma Northwest China</brief_title>
	<detailed_description>Nasopharyngeal carcinoma unique geographic distribution , different pathological type , natural history , treatment modality endemic non-endemic region . Nasopharyngeal carcinoma radiosensitive chemosensitive . Chemoradiotherapy main therapy choice locoregionally advanced nasopharyngeal carcinoma . However , optimal chemoradiotherapy regimen determine . Many new drug include docetaxel gemcitabine incorporate induction chemotherapy phase NPC . The investigator design present study induction chemotherapy follow CCRT locoregionally advance NPC non-endemic Northwest China , compare induction chemotherapy regime TP GP . The primary objective overall response rate ( ORR ) , acute toxicity , tolerance ; second objective overall survival ( OS ) , progression free survival ( PFS ) , rate distant metastasis , late adverse event quality life .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically prove WHO II~III native NPC northwest region China ; 18 Years 70 Years ; stag IIIIVb accord AJCC stage classification ( 7th edition ) , previous chemotherapy radiotherapy ; Performance status : 01 ( ECOG ) ; WBC &gt; 4.0X109/L , PLT &gt; 100X109/L , normal hepatic function ( AST , ALT &lt; 2.5 x upper limit normal , bilirubin &lt; 1.5 x upper limit normal ) , normal renal function ( Creatinine &lt; 1.5 x upper limit normal ) ; Ability comply trial requirement . Evidence metastases clinical radiographic examination ; History malignancy ; Prior chemotherapy anticancer biologic therapy type cancer , prior radiotherapy head neck region except radioactive iodine therapy . ; Patients uncontrolled intercurrent disease ; Patients currently active malignancy ; Pregnant lactate woman patient childbearing potential unwilling practice adequate contraception study treatment two month last administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Advanced Nasopharyngeal Carcinoma</keyword>
	<keyword>treatment</keyword>
	<keyword>Northwest China</keyword>
</DOC>